Dapagliflozin and Anemia Outcomes: A Systematic Review and Meta-Analysis of Effects on Hemoglobin Levels, Anemia Correction, and Incidence in Patients With and Without Heart Failure
Authors:
Open Access
- 20 October 2025
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 17 (10)
Abstract
This systematic review and meta-analysis evaluated the impact of dapagliflozin on anemia outcomes across different patient populations. A comprehensive literature search was conducted across multiple databases from inception to September 2025, identifying studies that reported anemia-related outcomes in adult patients receiving dapagliflozin treatment. Seven studies comprising 15,540 participants were included, encompassing randomized controlled trials and observational studies conducted across diverse geographical regions. All studies evaluated 10 mg of dapagliflozin once daily with a minimum four-week follow-up duration. The pooled analysis demonstrated significant improvements in hemoglobin levels with dapagliflozin compared to control groups (standardized mean difference [SMD]: 0.62; 95% CI: 0.43-0.80). Dapagliflozin treatment was associated with an 83% higher likelihood of anemia correction (relative risk: 1.83; 95% CI: 1.47-2.26) and a 78% reduction in anemia incidence (relative risk: 0.22; 95% CI: 0.08-0.60). Subgroup analyses revealed consistent benefits across all studied populations, with the most pronounced effects observed in heart failure patients (SMD: 0.78; 95% CI: 0.44-1.12), followed by chronic kidney disease (0.66; 95% CI: 0.36-0.95) and diabetes patients (0.45; 95% CI: 0.38-0.51). These findings suggest that dapagliflozin's therapeutic benefits extend beyond cardiovascular and renal protection to include meaningful improvements in anemia outcomes across multiple chronic disease states, potentially reducing healthcare burden and improving patient quality of life.Keywords
This publication has 34 references indexed in Scilit:
- Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicasNefrología, 2023
- Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 InhibitorsAdvances in Therapy, 2023
- Dapagliflozin and Anemia in Patients with Chronic Kidney DiseaseNEJM Evidence, 2023
- Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialThe Lancet Diabetes & Endocrinology, 2021
- Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysisInternational Urology and Nephrology, 2021
- Effect of dapagliflozin on anaemia in DAPA‐HFEuropean Journal of Heart Failure, 2021
- Correction of anemia by dapagliflozin in patients with type 2 diabetesJournal of Diabetes and its Complications, 2020
- Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal DisordersJACC: Basic To Translational Science, 2020
- Anaemia, Iron Deficiency and Heart Failure in 2020: Facts and NumbersESC Heart Failure, 2020
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004